Cardiac resynchronization therapy in CKD: A systematic review

Clinical Journal of the American Society of Nephrology

Volumn 8, Issue 8, 2013, Pages 1293-1303

  Garg, Neha ^a   Thomas, George ^a   Jackson, Gregory ^a   Rickard, John ^b   Nally, Joseph V ^a,c   Tang, W H Wilson ^a,c   Navaneethan, Sankar D ^a,c  

^a LERNER RESEARCH INSTITUTE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c CLEVELAND CLINIC LERNER COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT;

ARTICLE; CARDIAC RESYNCHRONIZATION THERAPY; CHRONIC KIDNEY DISEASE; DEATH; GLOMERULUS FILTRATION RATE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HOSPITALIZATION; HUMAN; RANDOMIZED CONTROLLED TRIAL (TOPIC); SURVIVAL; SYSTEMATIC REVIEW;

CARDIAC RESYNCHRONIZATION THERAPY; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RENAL INSUFFICIENCY, CHRONIC; RENIN-ANGIOTENSIN SYSTEM; VENTRICULAR FUNCTION, LEFT;

EID: 84881253220     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.00750113     Document Type: Article

References (45)

1. Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW, Eggers P, Van Lente F, Levey AS: Prevalence of chronic kidney disease in the United States. JAMA 298: 2038-2047, 2007.
2. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY: Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351: 1296-1305, 2004.
3. Park M, Hsu CY, Li Y, Mishra RK, Keane M, Rosas SE, Dries D, Xie D, Chen J, He J, Anderson A, Go AS, Shlipak MG; Chronic Renal Insufficiency Cohort (CRIC) Study Group: Associations between kidney function and subclinical cardiac abnormalities in CKD. J Am Soc Nephrol 23: 1725-1734, 2012.
4. Lash JP, Go AS, Appel LJ, He J, Ojo A, Rahman M, Townsend RR, Xie D, Cifelli D, Cohan J, Fink JC, Fischer MJ, Gadegbeku C, Hamm LL, Kusek JW, Landis JR, Narva A, Robinson N, Teal V, Feldman HI; Chronic Renal Insufficiency Cohort (CRIC) Study Group: Chronic Renal Insufficiency Cohort (CRIC) Study: Baseline characteristics and associations with kidney function. Clin J Am Soc Nephrol 4: 1302-1311, 2009.
5. Kane GC, Karon BL, Mahoney DW, Redfield MM, Roger VL, Burnett JC Jr, Jacobsen SJ, Rodeheffer RJ: Progression of left ventricular diastolic dysfunction and risk of heart failure. JAMA 306: 856-863, 2011.
6. Martin FL, McKie PM, Cataliotti A, Sangaralingham SJ, Korinek J, Huntley BK, Oehler EA, Harders GE, Ichiki T, Mangiafico S, Nath KA, Redfield MM, Chen HH, Burnett JC Jr: Experimental mild renal insufficiency mediates early cardiac apoptosis, fibrosis, and diastolic dysfunction: A kidney-heart connection. Am J Physiol Regul Integr Comp Physiol 302: R292-R299, 2012.
7. Kottgen A, Russell SD, Loehr LR, Crainiceanu CM, Rosamond WD, Chang PP, Chambless LE, Coresh J: Reduced kidney function as a risk factor for incident heart failure: The atherosclerosis risk in communities (ARIC) study. J Am Soc Nephrol 18: 1307-1315, 2007.
8. Lund LH, Benson L, Dahlström U, Edner M: Association between use of renin-angiotensin system antagonists and mortality in patients with heart failure and preserved ejection fraction. JAMA 308: 2108-2117, 2012.
9. Parikh NI, Hwang SJ, Larson MG, Meigs JB, Levy D, Fox CS: Cardiovascular disease risk factors in chronic kidney disease: Overall burden and rates of treatment and control. Arch Intern Med 166: 1884-1891, 2006.
10. Ezekowitz J, McAlister FA, Humphries KH, Norris CM, Tonelli M, Ghali WA, Knudtson ML; APPROACH Investigators: The association among renal insufficiency, pharmacotherapy, and outcomes in 6,427 patients with heart failure and coronary artery disease. J Am Coll Cardiol 44: 1587-1592, 2004.
11. Goldenberg I, Moss AJ, McNitt S, Barsheshet A, Gray D, Andrews ML, Brown MW, Zareba W, Sze E, Solomon SD, Pfeffer MA; Multicenter Automatic Defibrillator Implantation Trial-Cardiac Resynchronization Therapy Investigators: Relation between renal function and response to cardiac resynchronization therapy in Multicenter Automatic Defibrillator Implantation Trial- Cardiac Resynchronization Therapy (MADIT-CRT). Heart Rhythm 7: 1777-1782, 2010.
12. Goldberg RJ, Ismailov RM, Patlolla V, Lessard D, Spencer FA: Therapies for acute heart failure in patients with reduced kidney function: A community-based perspective. Am J Kidney Dis 51: 594-602, 2008.
13. Desai AS, Swedberg K, McMurray JJ, Granger CB, Yusuf S, Young JB, Dunlap ME, Solomon SD, Hainer JW, Olofsson B, Michelson EL, Pfeffer MA; CHARM Program Investigators: Incidence and predictors of hyperkalemia in patients with heart failure: An analysis of the CHARM Program. J Am Coll Cardiol 50: 1959-1966, 2007.
14. Epstein AE, Dimarco JP, Ellenbogen KA, Estes NA 3rd, Freedman RA, Gettes LS, Gillinov AM, Gregoratos G, Hammill SC, Hayes DL, Hlatky MA, Newby LK, Page RL, Schoenfeld MH, Silka MJ, Stevenson LW, Sweeney MO; American College of Cardiology; American Heart Association Task Force on Practice Guidelines; American Association for Thoracic Surgery; Society of Thoracic Surgeons: ACC/AHA/HRS 2008 Guidelines for device-based therapy of cardiac rhythm abnormalities. Heart Rhythm 5: e1-e62, 2008.
15. Tracy CM, Epstein AE, Darbar D, Dimarco JP, Dunbar SB, Estes NA 3rd, Ferguson TB Jr, Hammill SC, Karasik PE, Link MS, Marine JE, Schoenfeld MH, Shanker AJ, Silka MJ, Stevenson LW, Stevenson WG, Varosy PD: 2012 ACCF/AHA/HRS focused update of the 2008 guidelines for device-based therapy of cardiac rhythmabnormalities: A report of the american college of cardiology Foundation/American heart association task force on practice guidelines. Heart Rhythm 9: 1737-1753, 2012.
16. Linde C, Abraham WT, Gold MR, St John Sutton M, Ghio S, Daubert C; REVERSE (REsynchronization reVErses Remodeling in Systolic left vEntricular dysfunction) Study Group: Randomized trial of cardiac resynchronization in mildly symptomatic heart failure patients and in asymptomatic patients with left ventricular dysfunction and previous heart failure symptoms. J Am Coll Cardiol 52: 1834-1843, 2008.
17. Waggoner AD, Faddis MN, Gleva MJ, de las Fuentes L, Dávila-Román VG: Improvements in left ventricular diastolic function after cardiac resynchronization therapy are coupled to response in systolic performance. J Am Coll Cardiol 46: 2244-2249, 2005.
18. Bristow MR, Saxon LA, Boehmer J, Krueger S, Kass DA, DeMarco T, Carson P, DiCarlo L, DeMets D, White BG, DeVries DW, Feldman AM; Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) Investigators: Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 350: 2140-2150, 2004.
19. Moss AJ, Hall WJ, Cannom DS, Klein H, Brown MW, Daubert JP, Estes NA 3rd, Foster E, Greenberg H, Higgins SL, Pfeffer MA, Solomon SD, Wilber D, Zareba W; MADIT-CRT Trial Investigators: Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med 361: 1329-1338, 2009.
20. Abraham WT, Fisher WG, Smith AL, Delurgio DB, Leon AR, Loh E, Kocovic DZ, Packer M, Clavell AL, Hayes DL, Ellestad M, Trupp RJ, Underwood J, Pickering F, Truex C, McAtee P, Messenger J; MIRACLE Study Group. Multicenter InSync Randomized Clinical Evaluation: Cardiac resynchronization in chronic heart failure. N Engl J Med 346: 1845-1853, 2002.
21. Foley RN, Murray AM, Li S, Herzog CA, McBean AM, Eggers PW, Collins AJ: Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999. J Am Soc Nephrol 16: 489-495, 2005.
22. Hayden JA, Côté P, Bombardier C: Evaluation of the quality of prognosis studies in systematic reviews. Ann Intern Med 144: 427-437, 2006.
23. Lin G, Gersh BJ, Greene EL, Redfield MM, Hayes DL, Brady PA: Renal function and mortality following cardiac resynchronization therapy. Eur Heart J 32: 184-190, 2011.
24. Adelstein EC, Shalaby A, Saba S: Response to cardiac resynchronization therapy in patients with heart failure and renal insufficiency. Pacing Clin Electrophysiol 33: 850-859, 2010.
25. Shalaby A, El-Saed A, Voigt A, Albany C, Saba S: Elevated serum creatinine at baseline predicts poor outcome in patients receiving cardiac resynchronization therapy. Pacing Clin Electrophysiol 31: 575-579, 2008.
26. Fung JW, Szeto CC, Chan JY, Zhang Q, Chan HC, Yip GW, Yu CM: Prognostic value of renal function in patients with cardiac resynchronization therapy. Int J Cardiol 122: 10-16, 2007.
27. Van Bommel RJ, Mollema SA, Borleffs CJ, Bertini M, Ypenburg C, Marsan NA, Delgado V, Van Der Wall EE, Schalij MJ, Bax JJ: Impaired renal function is associated with echocardiographic nonresponse and poor prognosis after cardiac resynchronization therapy. J Am Coll Cardiol 57: 549-555, 2011.
28. Hyder ON, Buxton A, Nemr S, Ziv O, Lorvidhaya P, Ellison K: Advanced chronic kidney disease patients survive long enough to benefit from cardiac resynchronization therapy [Abstract]. Presented at Heart Rhythm, Denver, CO, May 12-15, 2010.
29. Rickard J, Kumbhani D, Baranowski B, Taigen T, Ingelmo C, Wilkoff B: The effect of cardiac resynchronization therapy on symptoms, ejection fraction, and long term outcomes in patients with renal dysfunction [Abstract]. Presented at Heart Rhythm, Boston, MA, May 13-16, 2009.
30. Funke F, Maran A, Klein M, Quin EM, Vest RN, Sturdivant JL, Leman RB, Cuoco F, Wharton M, Gold MR: The impact of renal function on survival following CRT implantation [Abstract]. Presented at Heart Rhythm, Denver, CO, May 12-15, 2010.
31. Cleland JG, Daubert JC, Erdmann E, Freemantle N, Gras D, Kappenberger L, Tavazzi L; Cardiac Resynchronization-Heart Failure (CARE-HF) Study Investigators: The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 352: 1539-1549, 2005.
32. Boerrigter G, Costello-Boerrigter LC, Abraham WT, Sutton MG, Heublein DM, Kruger KM, Hill MR, McCullough PA, Burnett JC Jr: Cardiac resynchronization therapy improves renal function in human heart failure with reduced glomerular filtration rate. J Card Fail 14: 539-546, 2008.
33. Tang AS, Wells GA, Talajic M, Arnold MO, Sheldon R, Connolly S, Hohnloser SH, Nichol G, Birnie DH, Sapp JL, Yee R, Healey JS, Rouleau JL; Resynchronization-Defibrillation for Ambulatory Heart Failure Trial Investigators: Cardiac-resynchronization therapy for mild-to-moderate heart failure. N Engl J Med 363: 2385-2395, 2010.
34. Kreuz J, Horlbeck F, Linhart M, Mellert F, Fimmers R, Schrickel J, Nickenig G, Schwab JO: Independent predictors of mortality in patients with advanced heart failure treated by cardiac resynchronization therapy. Europace 14: 1596-1601, 2012.
35. Jeevanantham V, Shanberg D, Saad A, Abu-El-Haija B, Dawn B, Lakkireddy D: Cardiac resynchronization therapy prevents progression of renal failure in heart failure patients [Abstract]. Circulation 124: A13947, 2011.
36. Singal G, Upadhyay GA, Friedman D, Chatterjee NA, Kandala J, Orencole M, Barrett C, Dec GW, Picard MH, Singh JP: Renal response in patients with chronic kidney disease (CKD) predicts outcome following cardiac resynchronization therapy (CRT) [Abstract]. Circulation 126: A17791, 2012.
37. Bai R, Di Biase L, Elayi C, Ching CK, Barrett C, Philipps K, Lim P, Pate lD, Callahan T, Martin DO, Arruda M, Schweikert RA, Saliba WI, Wilkoff B, Natale A: Mortality of heart failure patients after cardiac resynchronization therapy: Identification of predictors. J Cardiovasc Electrophysiol 19: 1259-1265, 2008.
38. Hosoda J, Ishikawa T, Matsushita K, Matsumoto K, Kimura Y, Miyamoto M, Ogawa H, Takamura T, Sugano T, Ishigami T, Uchino K, Kimura K, Umemura S: Impact of renal insufficiency on long-term clinical outcome in patients with heart failure treated by cardiac resynchronization therapy. J Cardiol 60: 301-305, 2012.
39. Verbrugge FH, Dupont M, Rivero-Ayerza M, de Vusser P, Van Herendael H, Vercammen J, Jacobs L, Verhaert D, Vandervoort P, Tang WH, Mullens W: Comorbidity significantly affects clinical outcome after cardiac resynchronization therapy regardless of ventricular remodeling. J Card Fail 18: 845-853, 2012.
40. Lattanzio MR, Weir MR: Does blockade of the renin-angiotensinaldosterone system slow progression of all forms of kidney disease? Curr Hypertens Rep 12: 369-377, 2010.
41. Amann K, Törnig J, Kugel B, Gross ML, Tyralla K, El-Shakmak A, Szabo A, Ritz E: Hyperphosphatemia aggravates cardiac fibrosis and microvascular disease in experimental uremia. Kidney Int 63: 1296-1301, 2003.
42. Amann K, Wanner C, Ritz E: Cross-talk between the kidney and the cardiovascular system. J Am Soc Nephrol 17: 2112-2119, 2006.
43. Buzello M, Boehm C, Orth S, Fischer B, Ehmke H, Ritz E, Mall G, Amann K: Myocyte loss in early left ventricular hypertrophy of experimental renovascular hypertension. Virchows Arch 442: 364-371, 2003.
44. Ronco C, Cicoira M, McCullough PA: Cardiorenal syndrome type 1: Pathophysiological crosstalk leading to combined heart and kidney dysfunction in the setting of acutely decompensated heart failure. J Am Coll Cardiol 60: 1031-1042, 2012.
45. Sarraf M, Masoumi A, Schrier RW: Cardiorenal syndrome in acute decompensated heart failure. Clin J Am Soc Nephrol 4: 2013-2026, 2009